We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| LadRx Corporation (QB) | USOTC:LADX | OTCMarkets | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.005 | -0.19% | 2.58 | 2.30 | 2.62 | 2.58 | 2.55 | 2.55 | 968 | 21:00:01 |
From Dec 2023 to Jun 2024
By Denny Jacob
Xoma will make a $1 million milestone payment to LadRx following the U.S. Food and Drug Administration's acceptance of Zevra Therapeutics' new drug application for arimoclomol.
"We, together with the NPC community, support Zevra's efforts to secure marketing approval for arimoclomol in the U.S. and the EU," said Xoma Chief Executive Brad Sitko.
The biotech royalty aggregator in June paid LadRx a $5 million upfront payment plus a share of future event-based milestones to acquire a mid-single digit royalty on arimoclomol's commercial sales and up to $52.6 million in potential milestone payments from Zevra, among other aspects.
Arimoclomol is a therapy for Niemann-Pick disease type C, a genetic disorder characterized by an ability of the body to transport cholesterol and other lipids inside of cells.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
January 11, 2024 16:35 ET (21:35 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year LadRx (QB) Chart |
1 Month LadRx (QB) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
